-
Riluzole
- indication:For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
- pharmacologypharmacology:
- mechanism: The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.
- toxicity:
- absorprion: Riluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.
- halflife: The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.
- roouteelimination:
- volumedistribution:
- clearance: